# EDGAR Filing Document

**Accession Number:** 0001503274
**File Stem:** 0001628280-26-034124
**Filing Date:** 2026-5
**Character Count:** 8634
**Document Hash:** 1cfe3b6ca43973e4507f5e3d3977a434
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-034124.hdr.sgml**: 20260512

**ACCESSION NUMBER**: 0001628280-26-034124

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260511

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260512

**DATE AS OF CHANGE**: 20260512

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Quanterix Corp
- **CENTRAL INDEX KEY:** 0001503274
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 208957988
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38319
- **FILM NUMBER:** 26968821

**BUSINESS ADDRESS:**
- **STREET 1:** 900 MIDDLESEX TURNPIKE
- **CITY:** BILLERICA
- **STATE:** MA
- **ZIP:** 01821
- **BUSINESS PHONE:** 617-301-9400

**MAIL ADDRESS:**
- **STREET 1:** 900 MIDDLESEX TURNPIKE
- **CITY:** BILLERICA
- **STATE:** MA
- **ZIP:** 01821

?xml version='1.0' encoding='ASCII'? qtrx-20260511

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

______________________________________

**FORM 8-K**

______________________________________

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 11, 2026**

_________________________________________________

**QUANTERIX CORPORATION**

(Exact name of registrant as specified in its charter)

_________________________________________________

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38319** | **20-8957988** |
| (State or other jurisdiction<br>of incorporation) | (Commission File Number) | (IRS Employer<br>Identification No.) |

---

---

| | |
|:---|:---|
| **900 Middlesex Turnpike** | |
| **Billerica, MA** | **01821** |
| (Address of principal executive offices) | (Zip Code) |

---

**(617) 301-9400**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class:** | **Trading symbol(s):** | **Name of each exchange on which**<br>**registered:** |
| Common Stock, $0.001 par value per share | QTRX | The Nasdaq Global Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company □

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

------

**Item 5.02&nbsp;&nbsp;&nbsp;&nbsp;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

Vandana Sriram will be leaving Quanterix Corporation (the "Company") and will no longer serve as the Chief Financial Officer and Treasurer of the Company effective June 15, 2026. Ms. Sriram will receive severance benefits in accordance with the terms of her employment agreement with the Company, as amended, consisting of the continued payment of her base salary for 12 months, payment of an amount equal to her annual target bonus for 2026, and subsidized health benefits for 12 months.

Ms. Sriram's departure is not related to any disagreements with the Company on any matter relating to its accounting practices, financial statements, internal controls, or operations.

The Company is conducting a search, with the assistance of a leading executive search firm, to identify a successor for the Chief Financial Officer position.

**Item 7.01&nbsp;&nbsp;&nbsp;&nbsp;Regulation FD Disclosure.**

On May 12, 2026, the Company issued a press release, which announced the pending departure of Ms. Sriram (the "Release"). A copy of the Release is attached as Exhibit 99.1 and incorporated herein by reference.

The information contained or incorporated in this Item 7.01, including Exhibit 99.1, is being furnished, and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

(d)Exhibits

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description** |
| 99.1 | <u>[Press Release dated May 12, 2026.](exhibit991-qtrxx20261205.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: May 12, 2026 | **QUANTERIX CORPORATION** | **QUANTERIX CORPORATION** |
|  | **By:** | /s/ Daniel S. Char |
|  | **Name:** | Daniel S. Char |
|  | **Title:** | Chief Legal Officer and Corporate Secretary |

---

## Exhibit 99.1

**Exhibit 99.1**

**Quanterix Announces Planned Transition of Chief Financial Officer**

BILLERICA, Mass.--May 12, 2026-- **Quanterix Corporation (Nasdaq: QTRX)**, a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that Vandana Sriram, its Chief Financial Officer ("CFO") will depart the Company. A search for her successor is ongoing, and Ms. Sriram will continue as CFO through June 15, 2026, to ensure continuity and a successful transition.

"Vandana has made impactful contributions to Quanterix since joining the Company in 2023," stated Everett Cunningham, President and Chief Executive Officer of Quanterix. "Her leadership and contributions have been instrumental in the ongoing evolution of the company and have helped create a strong foundation for cost discipline and cash management. I thank Vandana for her partnership during my tenure as CEO and wish her the very best in her next professional endeavor."

"Quanterix is on a solid financial footing, with a clear path to cash flow breakeven and achievement of challenging synergy targets and operating with solid financial discipline and rigor. I am honored to have worked with such a talented and dedicated team," commented Vandana Sriram. "It has been a privilege to be part of the company's journey, and I look forward to seeing the company's continued success."

**About Quanterix**

Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa<sup>®</sup> technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With approximately 6,300 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company<sup>®</sup>, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,439 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at www.quanterix.com.

Media

media@quanterix.com

Investor Relations

Joshua Young

ir@quanterix.com

<br>